Option Care Health Business Summary

Option Care Health, Inc. (OPCH) is the preeminent independent provider of home and alternate site infusion services in the United States, generating revenue through a service-intensive model that delivers complex clinical care and specialized pharmacy solutions. The company’s business is structured into two primary segments: Chronic Therapies, which accounts for approximately 75% of revenue and focuses on long-term conditions like immunoglobulin and autoimmune disorders, and Acute Therapies, comprising the remaining 25% for short-term needs such as anti-infectives and nutrition. Leveraging a national footprint of over 170 locations and 90+ pharmacies, OPCH maintains a 23-25% share of the domestic home infusion market. It competes directly with CVS Health’s Coram, UnitedHealth Group’s Optum Home Infusion, and specialized firms like InfuSystem and IVX Health, distinguishing itself as the dominant independent pure-play leader with superior scale for payer contracting and clinical density. The company’s lineage traces back to 1979, founded by pharmacists Michael Prime and Mitchell Hoggard, while the current corporate entity was solidified via the 2019 merger of Option Care Enterprises and BioScrip. Leadership is headed by President and CEO John C. Rademacher, who brings extensive healthcare pedigree from executive roles at Cardinal Health and CareFusion. The executive suite includes EVP and CFO Meenal Sethna, a 30-year finance veteran previously with Illinois Tool Works and Motorola, and CTO Brett Michalak, who oversees the firm’s digital health infrastructure. The company is governed by an independent board chaired by Harry M. Jansen Kraemer, Jr., former Chairman and CEO of Baxter International. Following the divestment of legacy stakes by Madison Dearborn Partners and Walgreens Boots Alliance, OPCH is now predominantly owned by institutional giants, including BlackRock and The Vanguard Group, which collectively hold nearly 98% of the company’s equity.